Could a common diabetes drug be the key to better stroke recovery?
NCT ID NCT07613437
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a GLP-1 receptor agonist (a type of diabetes medicine) can reduce brain swelling and improve recovery in people who have had a bleeding stroke. About 200 adults with a specific type of brain bleed will receive either standard care or the drug plus standard care. The goal is to see if the drug limits secondary brain injury and leads to better function.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRACEREBRAL HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chinese University of Hong Kong
Hong Kong, Hong Kong
-
The First Affiliated Hospital of University of Science and Technology China
Hefei, Anhui, China
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can blood markers predict brain injury outcomes?
- Can an ancient herbal pill improve outcomes after a bleeding stroke?
- Zapping the vagus nerve: a new hope for Stroke-Weakened arms?
- Ear nerve zaps may aid stroke recovery in kids — a tiny trial puts it to the test
- Could a gentle surgical approach improve outcomes after deep brain bleeding?
- Common ICU procedure may briefly raise brain pressure — study investigates the risk